---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092025"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-08-06T20:16:17+00:00"
generated_at: "2026-08-06T20:20:00.595168+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics

## Summary
- Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.
- Cash, equivalents, and marketable securities $20.1M at June 30, 2026, down from $41.8M at Dec 31, 2025.
- Net loss $14.9M for Q2 2026 vs $26.8M for Q2 2025; R&D expenses fell to $7.4M from $24.1M.
- Asset impairment costs of $5.1M from restructuring initiatives to reduce footprint and sell assets.
- LigaChem elected to continue LNCB74 development; NextCure eligible for future milestones and royalties.

## SEC filing metadata
- accession: 0001104659-26-092025
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-08-06T20:16:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/0001104659-26-092025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092025
- JSON: https://secwatch.observer/filing/0001104659-26-092025.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.